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SWITCHING TO GENERIC:
THE NEED FOR PHYSICIAN AND PATIENT
CONSENT WHEN SUBSTITUTING ANTIEPILEPTIC
MEDICATION
Evan H. Langdon*
The amount Americans spend each year on prescription drugs has
increased dramatically from 120 billion dollars in 1999 to 200 billion dollars
in 2005.1 Generic drugs are currently estimated to save consumers twenty
billion dollars a year 2 and can save consumers close to fifty percent on their
daily medication needs if they choose generic drugs instead of brand name
drugs.3 Congress and many federal agencies support the increased use of
generic drugs as an effective way to lower health care costs. 4 Health care
authorities worldwide are implementing policies that encourage the use of
generic drugs as a simple and effective way to control the cost of
* J. D. Candidate May 2009, The Catholic University of America, Columbus School of
Law; B.S. Mechanical Engineering 2002, Villanova University. The author wishes to
thank his wife, Jennifer, for her support and encouragement. Special thanks to Bill
Murphy, Director of State Government Relations, Epilepsy Foundation, for his expert
knowledge and guidance.
1. Kate Kellogg, There's Good News, Bad News in Drug Development, THE
UNIVERSITY RECORD, Sept. 18, 2000, http://www.ur.umich.edu/000I/SepI8_00/3.htm;
KAISER FAMILY FOUND., PRESCRIPTION DRUG TRENDS (2007), http://www.kff.org/rxdrugs
/upload/3057_06.pdf.
2. Jonathan D. Rockoff, Cost of Medicine Could Increase: Brand-Name
Drugmakers Target Generic Prescriptions, BALT. SUN, June 17, 2008, at IA.
3. See FDA, CTR. FOR DRUG EVALUATION & RESEARCH, SAVINGS FROM GENERIC
DRUGS PURCHASED AT RETAIL PHARMACIES (2004), http://www.fda.gov/cder/
consumerinfo/savingsfromgenericdrugs.htm; see also Epilepsy Foundation, Generic
Drugs: A Welcome Savings ... But Are They Right for All?,
http://www.epilepsyfoundation.org/generics/index.html (last visited Oct. 11, 2008)
[hereinafter Generic Drugs] (stating generic drugs currently save consumers eight to ten
billion dollars a year at retail pharmacies).
4. Generic Drugs, supra note 3.
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medication.5 Although substitution of cheaper generic alternatives can result
in significant cost savings, generic substitution can create risks for some
patients, especially for epileptic patients.
Epilepsy is a neurological condition that produces brief disturbances in the
normal electrical functions of the brain that affect a variety of mental and
physical functions.6 The condition occurs when the normal brain function
that delivers tiny electrical charges between nerve cells is interrupted by an
intense burst of electrical energy.7 Due to the unique nature of epilepsy,
there are various reasons that a seizure may occur and different parts of the
brain may be affected in different ways, making treatment exceptionally
difficult. In fact, for seventy percent of people living with epilepsy or
seizures, the cause of the condition is unknown.8 A cure for epilepsy does
not presently exist;9 however, many people living with epilepsy can prevent
seizures by regularly taking medication and actively communicating with
their physician. 10  More than three million Americans are treated for
epilepsy, most commonly with antiepileptic medication. 12  Antiepileptic
5. G. Kramer et al., Current Approaches to the Use of Generic Antiepileptic Drugs,
11 EPILEPSY & BEHAV. 46, 46 (2007).
6. Epilepsy Foundation, What is Epilepsy?, http://www.epilepsyfoundation.org/
about (last visited Oct. 11, 2008) [hereinafter What is Epilepsy?] (listing symptoms
ranging from "convulsions and loss of consciousness to some that are not always
recognized as seizures by the person experiencing them or by health care professionals:
blank staring, lip smacking, or jerking movements of arms and legs.").
7. Id.
8. Epilepsy Foundation, Seizures and Syndromes, http://www.epilepsyfoundation
.org/about/types/index.cfm (last visited Oct. 11, 2008) (The most frequent causes in the
remaining thirty percent are brain tumor or stroke, head trauma, poisoning, infection, and
maternal injury).
9. Epilepsy Foundation, Treatment Options: Medications, http://www.epilepsy
foundation.org/about/treatment/medications (last visited Oct. 11, 2008) [hereinafter
Treatment Options].
10. Id.
11. What is Epilepsy?, supra note 6; see National Conference of State Legislatures:
The Forum of America's Ideas, Condition-specific Drug Substitution Legislation:
Epilepsy, http://www.ncsl.org/programs/health/rx-substitution08.htm (last visited Oct.
11, 2008) [hereinafter Forum of America's Ideas] (stating "[a]pproximately 3.2 million
Americans suffer from Epilepsy, including 40% who are women of childbearing age.").
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drug therapy can be highly effective; however, "accurate prediction of an
individual's response to medication is not possible."'
13
This article will demonstrate that the measures currently in place to
protect epileptic patients are inadequate. With generic versions of four
major brand name antiepileptic drugs set to enter the market by 2010,
pharmacists should be required to obtain the notification and consent of both
the patient and the patient's physician before substituting any antiepileptic
drug for another antiepileptic drug.
In order to place the article's argument in context, Part I provides
background information related to the development of generic drugs. Part I
also explains the approval process for generic drugs, as well as the treatment
of epilepsy with antiepileptic drug therapy. Part 11 explains why substitution
of generic drugs for brand name drugs is encouraged and how the
substitution of antiepileptic drugs may be unavoidable. Moreover, Part II
shows how different groups of epileptic patients are affected by substitution
and who ultimately bears the burden of generic substitution of antiepileptic
drugs. Part III analyzes state legislation that restricts generic substitution of
antiepileptic drugs and demonstrates why it fails to protect people living
with epilepsy. Part IV provides a proposed statute that requires notification
and consent of the patient and the patient's physician prior to substitution of
an antiepileptic medication. The article concludes in Part V with a look at
the potential means for protecting epileptic patients from unprompted
changes in treatment.
I. THE PROBLEMS ASSOCIATED WITH THE GENERIC SUBSTITUTION OF
ANTIEPILEPTIC DRUGS
A. Developing Brand Name and Generic Drugs
The average cost to drug companies in researching, developing, and
creating a new Food and Drug Administration (FDA) approved drug is 802
million dollars. 14  This cost can reach nearly 1.7 billion dollars when
12. Treatment Options, supra note 9.
13. Epilepsy Foundation, Drug Formularies and the Availability of Antiepileptic
Medications, http://www.epilepsyfoundation.org/advocacy/govaff/ppl.cfm (last visited
Oct. 11, 2008) [hereinafter Drug Formularies].
14. PHRMA, WHAT GOES INTO THE COST OF PRESCRIPTION DRUGS? ... AND OTHER
QUESTIONS ABOUT YOUR MEDICINES 2 (2005), http://www.phrma.org/files/
Cost of PrescriptionDrugs.pdf [hereinafter PHRMA] (citing J.A. DiMasi, R.W. Hansen
& H.G. Grabowski, The Price oflnnovation: New Estimates of Drug Development Costs,
22 J. HEALTH ECON. 151, 151-85 (2003)).
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factoring in failed drug candidates. i s The majority of the cost is attributed to
the FDA's comprehensive pre-market approval process that is required by
the Federal Food, Drug, and Cosmetic Act (FDCA). 6 The FDA approval
process averages 8.2 years, 17 increasing the estimated time to discover and
develop a new drug to twelve to fifteen years.' 8 The Patent Act provides
drug companies the right to patent new drugs and offers market exclusivity
to sell and market a new drug for a term of twenty years. 9 The lengthy
FDA approval process effectively shortens the patent term,2 ° thereby
shortening the period of time during which research and development costs
can be recovered. The drug com anies then seek to recover these costs from
consumers through higher prices.
Generic versions of drugs can actively participate in domestic and global
markets once the patent rights of a brand name drug expire.22 Generic drugs
are sold at cheaper prices because manufacturers take advantage of a brand
name drug's existing research and development. 23  Congress passed the
15. Ann M. Thayer, Blockbuster Model Breaking Down: Pharma Industry Reaches
New Sales Peak, Despite Rising Costs and Bigger Challenges for Drug R&D, MODERN
DRUG DISCOVERY 23, 23 (2004).
16. Thomas Noud & Paul Meiklejohn, The Developing Law of Pharmaceutical
Patent Enforcement, 87 J. PAT. & TRADEMARK OFF. Soc'Y 921, 921 (2005).
17. Id.
18. PHRMA, supra note 14, at 2.
19. 35 U.S.C. § 154(a)(1) (2000) ("Every patent shall ... grant to the patentee...
the right to exclude others from making, using, offering for sale, or selling the invention
throughout the United States or importing the invention ... [and] the right to exclude...
products made by that process, referring to the specification for the particulars thereof.");
35 U.S.C. § 154(a)(2) (2000) (limiting a patent term to a period of twenty years from the
date of filing of the patent application).
20. Noud & Meiklejohn, supra note 16, at 921.
21. Allison Ladd, Integra v. Merck: Effects on the Cost and Innovation of New Drug
Products, 13 J.L. & POL'Y 311, 312 (2005).
22. Id.
23. Id. at 312-13 (stating patent laws require full disclosure of patented inventions
thereby allowing generic drug manufacturers to obtain necessary information on
submissions of brand name drugs in order to develop and manufacture generic versions).
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Drug Price Competition and Patent Term Restoration Act of 1984 as a
means of controlling rising drug prices. 24  Commonly referred to as the
"Hatch-Waxman Act," this law simplified FDA approval of generic drugs by
permitting drug manufacturers to obtain FDA approval of bioequivalent
versions of a brand name drug through an Abbreviated New Drug
Application (ANDA).25
B. The FDA's Criteria for Bioequivalent Generic Drugs
In order to gain approval, the generic drug company must show
bioequivalence of the generic and brand name drug. 26 Bioequivalence is
shown when the active ingredient in the generic drug has an equivalent
release and an equivalent rate and extent of absorption in comparison to the
Patent law, however, prohibited generic drug companies from engaging in the premarket
approval process required by the FDA until after the brand name patent had expired. Id.
at 313 (citing Roche Prod. Inc. v. Bolar Pharm. Co., 733 F.2d 858 (Fed. Cir. 1984)
(holding that performance of experiments to derive FDA required test data, conducted
with a view towards the adaptation of the patented invention to the experimenter's
business is a violation of patentee's right to exclude others from using his patented
invention)). This effectively extended the patent rights of the brand name drug company.
Noud & Meiklejohn, supra note 16, at 922.
24. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No.
98-417, 98 Stat. 1585 (1984); Noud & Meiklejohn, supra note 16, at 922; Ladd, supra
note 21, at 313.
25. Noud & Meiklejohn, supra note 16, at 922. The Hatch-Waxman Act also
included a "safe harbor" provision excluding from patent infringement "all activities
related to the gathering of information required for compliance with federal laws that
regulate drugs." Ladd, supra note 21, at 314. The "safe harbor" provision allows generic
companies to engage in the FDA approval process without infringing on the brand name
drug's patent rights to enable them to access the market more quickly. Id. at 314-15
(quoting Integra Life Sciences I, Ltd. v. Merck KGaA, 331 F.3d 860, 867 (Fed. Cir.
2003) (holding "that the safe harbor does not reach 'any exploratory research that may
rationally form a predicate for future clinical tests."')). In effect, this decision limits the
safe harbor protection to "generic drug manufacturers that seek FDA approval for
products that compete with existing brand name drugs." Id. at 315.
26. P. Crawford et al., Are There Potential Problems with Generic Substitutions of
Antiepileptic Drugs? A Review of the Issues, 15 SEIZURE 165, 166 (2006), available at
http://www.sciencedirect.com/science/joumal/10591311 (follow "Volume 15 (2006)"
hyperlink; then follow "Volume 15, Issue 3" hyperlink; then follow "PDF 167K"
hyperlink under number 6).
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active ingredient in the brand name drug product.27  The "concept of
bioequivalence is ... that ... if a drug product contains a drug substance
that is chemically identical and is delivered ... at the same rate and extent as
another drug product, then it is equivalent and can be substituted for that
drug product." 28 A variety of methods to determine bioequivalence can be
used depending on the type of drug tested.29 The FDA's position is that "[i]f
one therapeutically equivalent drug is substituted for another, the physician,
pharmacist, and patient have FDA's assurance that the physician should see
the same clinical results and safety profile."
30
Generic drugs must have the same active ingredient as their brand name
equivalent; however, they do not need to have the same inactive ingredient.
31
The FDA does not require exact equivalence. Current FDA guidelines allow
bioequivalence of a generic drug to range between 80% and 125% when
compared to the brand name drug.32 This means that despite the effects of
inactive ingredients present in a generic drug, the generic drug must only
demonstrate that the active ingredient is delivered at a rate that is between
80% and 125% when compared to the brand name drug.33 Based on the
approval process for generic drugs, exact equivalence is an impossible bar to
27. FDA, CTR. FOR DRUG EVALUATION & RESEARCH, APPROVED DRUG PRODUCTS
WITH THERAPEUTIC EQUIVALENCE EVALUATIONS viii (28th ed. 2008), available at
http://www.fda.gov/cder/orange/obannual.pdf [hereinafter ORANGE BOOK]; 21 C.F.R. §
320.23 (2008).
28. ORANGE BOOK, supra note 27, at viii.
29. Id; 21 C.F.R. § 320.24 (2008).
30. Letter from Roger L. Williams, M.D., Deputy Center Director for
Pharmaceutical Science, Ctr. for Drug Evaluation & Research, to Carmen A. Catizone,
Executive Director/Secretary, National Ass'n of Boards of Pharmacy (Apr. 16, 1997),
http://www.fda.gov/cder/news/ntiletter.htm; ORANGE BOOK, supra note 27, at vii ("FDA
classifies as therapeutically equivalent those products that ... are approved as safe and
effective . . . are pharmaceutical equivalents . . . are bioequivalent ... are adequately
labeled ... [and] are manufactured in compliance with [approved] regulations.").
31. Andrew N. Wilner, Therapeutic Equivalency of Generic Antiepileptic Drugs:
Results ofa Survey, 5 EPILEPSY & BEHAV. 995, 997 (2004).
32. ORANGE BOOK, supra note 27, at ix.
33. Id.
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clear because there are minor variations in the way people absorb drugs.
34
In addition, the generic drug may be manufactured differently, and this
process can influence dissolution rates in the digestive tract, and therefore
the absorption of the drug.35 The FDA has upheld a long-standing position
requiring major clinical evidence to demonstrate that a prior approved
generic drug is not bioequivalent.36 Without a showing of data to the
contrary, the FDA will conclude that the difference is too small to have a
substantial impact on patients.
37
C. The Inherent Problems with the FDA Approval Process
The FDA approval process requires a generic drug to contain the same
active ingredient as the brand name drug, but allows for different inactive
ingredients as long as bioequivalence falls within the acceptable range of
80% to 125%. 38  Once a generic drug is approved, the FDA requires
extensive evidence to rebut the presumption of bioequivalence, and courts
will show deference to the FDA's decision. 39  However, the acceptable
34. Sarah Rubenstein, Industry Fights Switch to Generics for Epilepsy, WALL ST. J.,
Jul. 13, 2007, at Al.
35. Kramer et al., supra note 5, at 48 (stating the differences in the "manufacturing
process used, in the excipients with which the active principle is associated in the final
drug product and the appearance of the drug product (shape, color, or both) . . . may
influence dissolution rates in the gastrointestinal tract and, thus, absorption of the drug
substance and overall pharmacokinetics.").
36. 21 C.F.R. § 320.33 (2008) states that:
The Commissioner of Food and Drugs shall consider ... well-documented
evidence [that] pharmaceutical equivalents . . . are not or may not be
bioequivalent drug products [based on] (a) Evidence from well-controlled
clinical trials or controlled observations in patients that such drug products
do not give comparable therapeutic effects. (b) Evidence from well-
controlled bioequivalence studies that such products are not bioequivalent
drug products. (c) Evidence that the drug products exhibit a narrow
therapeutic ratio ....
Id.
37. Rubenstein, supra note 34, at Al.
38. Wilner, supra note 31, at 997; ORANGE BOOK, supra note 27, at vi.
39. 21 C.F.R. § 320.33 (2008); see Warner-Lambert Co. v. Shalala, 202 F.3d 326,
331 (D.C. Cir. 2000) (upholding the FDA's decision to approve a new generic anti-
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bioequivalence range set by the FDA was not based on conclusive evidence,
but rather was "based on the opinions of FDA medical experts.
4 °
Considering that the parameters for bioequivalence were originally set by
opinions of "medical experts" and not fact-based evidence, it is irrational to
require a high level of conclusive evidence to show generic alternatives are
not bioequivalent. Other medical experts in the United States and around the
world have provided opinions regarding the flawed nature of the
bioequivalence standard4 1 and "recommend that doctors give explicit
approval for switches."
42
The FDA's approval process has another intrinsic flaw: the test for
bioequivalence is conducted on a small number of healthy adult volunteers,
"usually 24 to 36 adults." 43 One major problem with testing a small, limited
sample of healthy individuals is that the drug will eventually be used to treat
a larger number of patients whose existing illnesses or other treatments may
affect drug pharmacology.44 A second major problem is that establishing
seizure medication on the premise that it was therapeutically equivalent to the drug
Dilantin).
40. Wilner, supra note 31, at 997. These opinions are based on
[t]he statistical methodology for analyzing . . . bioequivalence .. .called
the two one-sided test procedure. Two situations are tested with this
statistical methodology. The first of the two one-sided tests determines
whether a generic product (test), when substituted for a brand-name
product (reference) is significantly less bioavailable. The second of the
two one-sided tests determines whether a brand-name product when
substituted for a generic product is significantly less bioavailable .. .
difference of greater than 20% for each of the above tests was determined
to be significant, and therefore, undesirable for all drug products.
ORANGE BOOK, supra note 27, at ix.
41. See, e.g., Wilner, supra note 31, at 995; Crawford et al., supra note 26, at 167-
69; Kramer et al., supra note 5, at 48; Dominic C. Heaney & Josemir W. Sander,
Antiepileptic Drugs: Generic Versus Branded Treatments, 6 LANCELOT NEUROLOGY 465,
467 (2007).
42. Rubenstein, supra note 34, at Al.
43. ORANGE BOOK, supra note 27, at viii; 21 C.F.R. § 320.24 (2008); Heaney &
Sander, supra note 41, at 466; Crawford et al., supra note 26, at 169.
44. Heaney & Sander, supra note 41, at 466; Pharmacology is "the properties and
reactions of drugs esp. in relation to their therapeutic value." MERRIAM-WEBSTER'S
COLLEGIATE DICTIONARY 868 (10th ed. 2001).
2008
Journal of Contemporary Health Law and Policy Vol. XXV: 166
bioequivalence in a group of healthy individuals is not synonymous with
establishing bioequivalence for an individual patient. For example,
individual epileptic patients respond to antiepileptic drugs in different ways,
making it difficult to establish bioequivalence for the group as a whole.
45
The third major problem is that test groups for bioequivalence usually do not
include children and the elderly, "two groups that make up a considerable
portion of patients receiving antiepileptic drugs. ' '46 Lastly, many patients
take more than just one drug. The presence of multiple medications can
affect how the drugs react in the patient. For example, an epileptic patient
may take more than one antiepileptic medication and other medications that
can affect the drug's absorption rate and behavior. 47 Currently, studies have
not been conducted and empirical evidence is not available on the
bioequivalence of antiepileptic medications in multiple-medicated epileptic
48patients. Moreover, a brand name antiepileptic drug made by a single
company has only one brand and method of manufacturing, but a generic
antiepileptic drug can be made by multiple companies and by multipleS- 49
manufacturing methods within FDA guidelines. 9  Due to these possible
differences, as well as the individual characteristics of each patient, the
bioequivalence of different antiepileptic medications cannot be presumed.
D. Treating Epileptic Patients with Antiepileptic Drugs
Close to seventy percent of epileptic patients can be seizure-free if they
maintain an appropriate drug and dose regimen. 50 Obtaining freedom from
seizures requires "rigid adherence" to a carefully ad justed drug regimen and
close monitoring by the patient's physician. Monitoring patients is
45. See Heaney & Sander, supra note 41, at 465; see Crawford et al., supra note 26,
at 168.
46. Kramer et al., supra note 5, at 49.
47. Id.
48. Id.
49. Steven C. Schachter, Chair, Epilepsy Found. Advisory Comm. on Generic
Antiepileptic Drugs, Address at Epilepsy Foundation's Annual Leadership Conference:
Protecting Patient Access to Safe and Effective Epilepsy Medications (Sept. 28, 2007).
50. Heaney & Sander, supra note 41, at 465.
51. Id. (drug regimens usually involve taking medication up to three times a day for
many years or for life); Crawford et al., supra note 26, at 168.
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difficult for a number of reasons. Wide variations in each person's response
to treatment, for example, have led physicians to recommend that changes or
substitutions to prescribed regimens be made over several weeks or
52months. Due to the long titration process to determine the proper dosage,
many physicians and patients are reluctant to make changes once stability is
attained.5 3
There are three main groups of epileptic patients: patients initiating
antiepileptic drug therapy, patients controlled by antiepileptic drug therapy,
and patients who are not well-controlled, or considered high-risk patients.
54
The goal for each group is to establish long-term stable treatment and the
avoidance of seizures once a patient has become seizure-free. 55 Abrupt
changes in a patient's medication can result in a "breakthrough seizure," a
seizure that "occurs unexpectedly while on drug therapy."56 After a period
of stability, the impact of a single seizure can have serious social
implications, such as the loss of one's driver's license or employment.
57
Personal implications can include physical injuries or the loss of self-
esteem. 58 In addition, "the risk of death in patients with uncontrolled
seizures is higher than in patients with controlled seizures." 59 These external
factors are unique to treating epilepsy, as changing medications designed to
52. Heaney & Sander, supra note 41, at 465; Crawford et al., supra note 26, at 168.
53. Crawford et al., supra note 26, at 168.
54. Kramer et al., supra note 5, at 50-51.
55. Crawford et al., supra note 26, at 167.
56. Epilepsy Foundation, Terms, http://www.epilepsyfoundation.org/generics/
glossary.html (last visited Oct. 11, 2008).
57. Crawford et al., supra note 26, at 167 (listing loss of driver's license and loss of
employment as social implications).
58. Id. (listing risk of injury and loss of self-esteem as personal implications). See
also Susan Spencer, Epilepsy: Clinical Observations and Novel Mechanisms, 6 THE
LANCET NEUROLOGY 14 (2006) (suggesting people diagnosed with epilepsy are three
times more likely to commit suicide than the general population).
59. Crawford et al., supra note 26, at 167.
2008
Journal of Contemporary Health Law and Policy Vol. XXV: 166
treat other conditions does not present the same personal and social
consequences.
60
Antiepileptic drugs have a narrow therapeutic index, meaning there is a
small difference between a high dosage that is toxic and a low dosage that is
ineffective. 61 A narrow therapeutic index combined with the wide variation
in responses to treatment among individual patients creates the risk of
different therapeutic responses to antiepileptic drugs defined as
bioequivalent. 62  Generic drugs are only tested for bioequivalence when
compared to brand name counterparts; they are not tested for bioequivalence
when compared to other generic drugs. 63 The current bioequivalence
standard set by the FDA "raises the possibility that the bioequivalence of
different [generic drugst may fall outside the acceptable range" when
compared to each other. Patients may be switched from one generic drug
whose bioequivalence is at the top of the acceptable range to a different
generic drug whose bioequivalence is at the bottom of the acceptable
range.65  The problem is not simply switching from a brand name
antiepileptic drug to a generic antiepileptic drug; the same problem is also
present when switching from a generic drug to another generic drug, or from
a generic drug back to a brand name drug.
60. See id
61. Id. An inadequate amount of the active ingredient will not affect the patient,
whereas too much of the active ingredient can cause adverse effects. In addition to
possible breakthrough seizures, possible toxic effects include sedation, lethargy,
cognitive and coordination impairment, rashes and gastrointestinal problems. Schachter,
supra note 48.
62. Crawford et al., supra note 26, at 168-69 (listing factors that increase the
likelihood of problems with generic substitution: low water solubility, narrow therapeutic
range, and nonlinear pharmacokinetics).
63. Kramer et al., supra note 5, at 48.
64. Id.
65. Crawford et al., supra note 26, at 169; see also Kramer et al., supra note 5, at 48
(explaining "if generic form A provides a peak plasma concentration of 124% of the
reference [drug], and generic form B provides concentrations of 81% of the reference
[drug], then both are considered to be bioequivalent to the reference [drug]. However,
the plasma concentrations obtained in B will only be 65% of those attained in A.").
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II. THE SWITCH TO GENERIC ANTIEPILEPTIC DRUGS
A. Requiring Epileptic Patients to Switch to Generic Antiepileptic Drugs
Due to rising healthcare costs, most prescription drug purchases in the
United States are paid for, at least in part, by employer-sponsored health
insurance plans, health maintenance organizations (HMOs), or by
66government programs like Medicaid and Medicare. It has become
commonplace for health program providers to establish drug formularies.
67
A drug formulary is a list of approved medications that are subsidized in part
by a particular plan. Drug formularies were developed to control spending
on prescription drugs.69  Incentive-based formularies place brand name
drugs on a higher cost tier than generic drugs.7° This formulary creates an
incentive to choose prescrition drugs from the lower cost tier, generating
savings for the health plan.
Another type of drug formulary is the Medicaid formulary, which does not
have tiers or incentives. 72 The drugs listed on the Medicaid formulary are
66. Abbott Lab. v. Andrx Pharm., Inc., No. C 1490, 2005 WL 1323435, at *15 (N.D.
Ill. June 3, 2005); Drug Formularies, supra note 13; see generally Jack Hoadley,
Elizabeth Hargrave, Katie Merrell, Juliette Cubanski & Tricia Neuman, Benefit Design
and Formularies of Medicare Drug Plans: A Comparison of 2006 and 2007 Offerings, A
First Look (2006), available at http://www.kff.org/medicare/upload/7589.pdf.
67. Drug Formularies, supra note 13.
68. Abbott Lab., 2005 WL 1323435, at * 15.
69. Drug Formularies, supra note 13.
70. Cindy Parks, Incentive-Based Formularies, 349 NEw ENGL. J. MED. 2186, 2186
(2003). Incentive-based formularies are typically divided into three tiers. The first tier
comprises low cost generic products, the second tier comprises "preferred branded"
products and the third tier comprises "non-preferred branded" products. Patients are
required to pay more for drugs listed on a higher tier than for a drug of the same price
listed on a lower tier. Abbott Lab., 2005 WL 1323435, at * 15.
71. Parks, supra note 70, at 2186 ("[T]he amount of copayments depend[s] on the
type of drug prescribed; the contracts among the insurer, the manufacturer, and the
pharmacy; and the price differential between the selected drug and reasonable low-cost
substitutes.").
72. Abbott Lab., 2005 WL 1323435, at *15.
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covered by the program.73 If a drug is not listed on the formulary, the
patient must pay for its cost out-of-pocket. 74 Medicare's programs include
both tiered and non-tiered formularies. 5 When a brand name medication
becomes available in the generic form, providers add the generic to their
formulary on the lowest-cost tier and then move the branded product to a
higher tier.7 6 Some plans, such as Medicaid, "remove the branded drug from
their formulary altogether., 7   Step-therapy formularies are two-step
programs that require the use of a generic drug first, and then a preferred
brand name drug, before the program will cover a non-preferred brand name
drug.78 Referred to as the "fail-first" formulary, 79 the program stipulates that
the "[u]se of non-preferred brand products without prior use of generic and
preferred brand products will require Prior Authorization (PA)."8  With
regard to epilepsy, "'failure' means having a seizure.
81
All fifty states permit pharmacists, under certain circumstances, to
substitute a generic drug even though a physician has prescribed a brand
73. Id.
74. Id. If a doctor prescribes a drug not listed on the Medicaid patient formulary,
"the patient must pay the entire cost out-of-pocket." Id.
75. See generally Hoadley et al., supra note 66.
76. Abbott Lab., 2005 WL 1323435, at * 15.
77. Id.
78. CIGNA PHARMACY MANAGEMENT, PARTICIPATING PHARMACY NEWSLETTER
(2007), available at http://www.cigna.com/customercare/healthcareprofessional/
pharmacy/newsletter/200708.pdf [hereinafter CIGNA].
79. JEFFREY CROWLEY, DEB ASHNER & L1NDA ELAM, THE KAISER COMM'N ON
MEDICAID AND THE UNINSURED, MEDICAID OUTPATIENT PRESCRIPTION DRUG BENEFITS:
FINDINGS FROM A NATIONAL SURVEY, iii (2003), available at http://www.kff.org/
medicaid/4164.cfm (follow "report" hyperlink).
80. CIGNA, supra note 78.
81. Eric Hargis, President and Chief Executive Officer, Epilepsy Found., Remarks at
American Medical Association Media Briefing on Antiepileptic Drug Guidelines (Apr.




name drug. If a generic drug is available, thirty states mandate the
substitution.8 3 The states permitting substitution encourage the use of
generics by "aggressively managing the Medicaid prescription drug
benefit."84 In comparison to generic drug policies in other countries, only
France and the United Kingdom have outlawed generic substitution of brand
name drugs.
85
Not all substitutions are due to state requirements or health care provider
incentives. The market for particular generic drugs may not be flooded with
suppliers. 86  Recent trends show that companies that have traditionally
produced brand name products now produce generic drugs directly, or have
wholly owned subsidiaries that produce them.87 This arrangement stifles the
anticipated competition between generic drug producers and brand name
82. Thomas P. Christensen et al., Drug Product Selection: Legal Issues, 41 J. AM.
PHARM. Ass'N 868, 869 (2001), available at http://www.medscape.com (register for the
site; then search "Drug Product Selection Legal;" then follow "Drug Product Selection:
Legal Issues" hyperlink).
83. CROWLEY, AsHNER & ELAM, supra note 79, at iv (noting "30 of 43 states
reporting in 2003" as compared to 16 of 44 states in 2000).
84. Id. at iii-vi ("Nearly half of the states (18 of 43 states reporting in 2003) operate
[Preferred Drug Lists]" and "[t]hirty-five of 43 states in 2003 reported cost sharing for
prescription drugs .... " In addition, thirty of forty-three states "track 'high-cost' users
of prescription drugs" and twenty-four of forty-three states "track 'high-prescribing'
physicians .... ").
85. Lisa S. Haskins et al., Patient and Physician Reactions to Generic Antiepileptic
Substitution in the Treatment of Epilepsy, 7 EPILEPSY & BEHAV. 98, 99 (2005).
Pharmacists in Germany are required to substitute a generic drug when the patent of a
brand name drug has lost protection or when there is a cheaper generic available. Other
countries, including Spain and Canada, do not require substitution when a cheaper
generic is available, but pharmacists are not required to consult a physician in order to
substitute a generic. Id.
86. Heaney & Sander, supra note 41, at 467.
87. Id. (noting that Novartis, the world's sixth largest producer of brand name drugs,
is also one of the world's largest producers of generic drugs); see also Kramer et al.,
supra note 5, at 48 (stating that when a drug company makes a generic copy of their own
drug, a common manufacturing process is used and the generic copy is often identical to
the brand name drug. The problems associated with generic substitution are not at issue
for "manufacturer's own" generics).
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drug producers. There are a small number of antiepileptic drug producers
who rely on the profitability of individual drugs.88  These drug
manufacturers are under no obligation to continue producing drugs if their
profits decrease. 89 As a result, a patient who is prescribed the cheapest
generic drug may be forced to switch between brand name drugs and
different forms of generic drugs as drug producers enter and exit the
market.9° Supply of antiepileptic drugs is not guaranteed and patients may
be subject to many switches over time. It is important that these switches be
monitored by a physician.
91
B. The Savings from Generic Drugs vs. The "Cost" to Epilepsy Patients
Generic drug use can help reduce the cost of prescription drugs; however,
the difference in price between a brand name drug and a generic drug should
92not be the only cost considered. The cost of generic prescribing includes
more than just the price of the generic drug.93 When the substitution causes
problems, additional costs are incurred from visits to the physician and to the
emergency room.9 4  Money will also be spent on additional clinical
appointments and education for patients about the changes.
95
The greatest "cost," however, cannot be measured in dollars if treatment
fails and a seizure occurs. 96 A breakthrough seizure might occur at work or
while driving, and could result in the epileptic patient losing his or her job or
driver's license. Moreover, the epileptic patient's life, and the lives of
others, would be put at risk. Besides the physical consequences, the loss of
seizure control can have a significant psychological impact on an epileptic




92. Crawford et al., supra note 26, at 169.
93. Id.
94. Id.
95. Heaney & Sander, supra note 41, at 467.
96. Crawford et al., supra note 26, at 169.
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patient's lifestyle, mood, and educational opportunities. The social
consequences and personal impact of just one breakthrough seizure in a
stabilized patient is so high that it could offset any money saved by a switch
to generic drugs.
98
C. Treating Different Groups of Epilepsy Patients
Patients initiating antiepileptic drug therapy, patients whose epilepsy is
successfully managed by antiepileptic drug therapy, and high-risk patients
are all susceptible to the problems presented by generic substitution. For
patients initiating antiepileptic therapy, physicians may choose between
brand name and generic drugs. When establishing long-term treatment,
physicians must be aware of the possibility of substitution if a brand name
drug is prescribed, the multiple generic forms of a particular antiepileptic
drug, and the stability of supply of both the brand name and generic drugs.
99
Another concern is the possibility that the patient will experience an allergic
reaction to the non-active ingredients in different generic drugs.100 Despite
careful planning by a physician with regard to the initial prescription, it is
difficult to guarantee that the patient will remain on the same drug.'01 In
order to obtain safe, long-term treatment of epilepsy, the physician must be
well-informed and the patient must be well-monitored.
The goal for patients who are well-controlled on antiepileptic drug therapy
is to avoid relapse. 10 2  Patients whose epilepsy is controlled with drug
therapy represent the group most affected by generic substitution and should
not be switched to another drug, although the switch is sometimes
97. Schachter, supra note 49.
98. Id.; Heaney & Sander, supra note 41, at 467 (stating that despite "the willingness
to accept policies of generic prescribing on the basis of cost, there is no data to quantify
the overall economic benefits of switching to the cheapest available brands.").
99. Kramer et al., supra note 5, at 50-51.
100. Id. at 50.
101. See Drug Formularies, supra note 13; see Christensen et al., supra note 82, at
869; see Heaney & Sander, supra note 41, at 467.
102. Kramer et al., supra note 5, at 50.
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unavoidable. 10 3 A decision to switch drugs should be planned in advance
and monitored by the patient's physician.' °4 Pharmacists must be educated
about the risks associated with generic substitution as well as the importance
of informing the physician and patient when making substitutions.
105
Patients who are inadequately controlled on antiepileptic therapy and
high-risk patient groups are more likely to be closely monitored by a
physician. However, a substitution during this stage of treatment, without
the knowledge or consent of the physician, can have devastating effects. A
physician cannot accurately monitor and adjust a patient's antiepileptic
therapy if he or she is unaware of any changes made to the medication.
Once new treatment has begun, the physician faces the same problems as
when the antiepileptic drug therapy was first initiated. 10 7 If seizure control is
reached, then the same issues with respect to well-controlled patients are
present. 10 8 The pharmacist, the physician, and the patient need to work
together to obtain stable results, regardless of which group of patients is
being treated.
D. Who Bears the Legal Burden of Generic Substitution ofAntiepileptic
Drugs?
The legal issues related to generic substitutions are not clear., °9 Legal
commentaries suggest that drug manufacturers' and physicians' exposure to
103. Id. at 50-51 ("For well-controlled patients with epilepsy, guidelines recommend
that patients should not be switched from branded drugs to generics, between generic
forms, or from generics to branded drugs due to the risk of loss of seizure control.").
104. Id. (suggesting patients keep a detailed diary to record the date of the switch and
any seizures or unfavorable results before and after the switch); Haskins et al., supra note
85, at 104-05.
105. Id. at 50.
106. Id. (identifying high-risk epilepsy patients as children, the elderly, those with
hepatic and renal dysfunction, those who drink and smoke, women of child bearing age,
patients with comorbid conditions or taking comedication, and those with cognitive
disabilities).
107. Id.
108. Kramer et al., supra note 5, at 51.
109. Heaney & Sander, supra note 41, at 467.
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liability will remain the same. 110 Drug manufacturers will continue to be
liable for injuries caused by defective products, and physicians are still
expected to exercise reasonable care when making prescriptions for their
patients. I"' Pharmacists, however, are taking on new responsibilities that
could expose them to liability for injuries caused when generic drugs are
112substituted for prescribed brand name or prescribed generic drugs. To
date, there are no appellate cases finding pharmacists liable for damages
caused by generic substitution. In fact, there are only two reported cases
involving drug product selection, and the plaintiff in both cases was
unsuccessful in establishing pharmacist liability."'
The issue is further complicated because many physicians and patients are
unaware of the potential for breakthrough seizures that can occur when a
pharmacist substitutes an antiepileptic medication prescribed to a controlled
epileptic patient with a bioequivalent antiepileptic medication.14 A study of
patients and physicians revealed that both groups were not well informed
regarding generic antiepileptic drugs.1 15 Without the proper information, it
is not clear whether the physician or the patient can adequately consent to a
substitution. 16 What constitutes legally informed consent for antiepileptic
substitution has not been established, nor has the burden of liability if
informed consent of the physician or the patient is not obtained. 17 Epileptic
110. Christensen et al., supra note 82, at 869.
111. Id.
112. Id.
113. Id. (citing Ullman v. Grant, 450 N.Y.S.2d 955 (N.Y. Sup. Ct. 1982) (holding the
pharmacist not liable when the physician wrote "substitution permitted" on the
prescription)); Bichler v. Willing, 397 N.Y.S.2d 57 (N.Y. App. Div. 1977) (holding the
pharmacist not liable for substituting a prescribed drug by a different manufacturer to a
pregnant woman whose daughter later developed severe permanent injury due to the
medication; in dicta, the court considered whether the pharmacist's choice of brands,
when other brands were available, would have made a difference in determining
liability).
114. Id.
115. Crawford et al., supra note 26, at 170.
116. Id.
117. Id.
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patients only marginally benefit from generic antiepileptic drug substitution
if they directly pay for their own medications, yet they bear the burden of
any complications that may result.
11 8
III. LEGISLATION TO INFORM PATIENTS AND PHYSICIANS ABOUT
SWITCHING TO GENERIC ANTIEPILEPTIC DRUGS
A. The Epilepsy Foundation's Position on Generic Substitution
The Epilepsy Foundation (the "Foundation") has opposed mandatory
substitution of generic drugs since they first became available. In a
statement posted on the Foundation's website, the Foundation stated that it
"is seriously concerned about mandatory substitution of generic antiepileptic
drugs without prior approval of the patient and treating physician."'19 The
Foundation "strongly advises . . . [those] who make [medication] decisions
. . .[to] address the potential adverse effects of changing from one
formulation of an anti-epileptic [sic] drug to another, by requiring the prior
expressed permission of the treating physician and the patient.'
120
The Foundation has focused its lobbying efforts on the FDA, Congress,
and state legislatures. The Foundation has sought to have the FDA narrow
the range of bioequivalence and modify the approval procedure, but has
been unable to provide the evidence necessary to support its request.
121
Enrolling patients in major clinical trials to establish the evidence required to
demonstrate that seizures are the direct effect of switches to generic
antiepileptic drugs would be difficult and cost prohibitive. 22  Because
antiepileptic drugs affect individuals differently, the few clinical trials that
have evaluated therapeutic equivalence have been met with mixed results
and have found difficulty proving that particular adverse events were
118. Id. (stating patients directly paying for medical costs would benefit by the lower
cost of the generic medication).
119. Epilepsy Foundation, Health Care Reform: Statement on Substitution of Generic
Antiepileptic Drugs, http://www.epilepsyfoundation.org/advocacy/care/genedrev.cfm
(last visited Oct. 11, 2008).
120. Id. (emphasis added) (advising rulemaking bodies, medical plans, hospitals,
correctional facilities, residential facilities and others who make medical decisions).
121. Rubenstein, supra note 34, at Al (citing FDA's response to the alleged
bioequivalence problem as: "Show us the data.").
122. Id.
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directly attributed to generic drug substitutions. 123 While the results may not
be conclusive, the few studies that have been conducted are compelling. A
postal survey of neurologists found that, of the 289 that responded, sixty-
eight percent reported breakthrough seizures and fifty-six percent reported
"increased adverse events" when an epileptic patient was switched from a
brand name to a generic antiepileptic drug. Another study identified eight
adult patients whose seizures not only worsened in effect but also increased
in frequency after their medications were switched from the brand Phenytoin
(PHT) to its generic form. 125 The obvious problem with conducting major
clinical trials is the exposure of patients to breakthrough seizures, which is
the very problem sought to be avoided.
Although the Foundation has lobbied Congress to enact legislation that
will carve out an exception for antiepileptic drugs, the Foundation has
focused its efforts on state legislation because states often move faster than
Congress. 126  Patent rights for Zonegran expired in 2005, and there are
already seventeen different generic manufacturers. Four additional major
brand name drugs will expire between 2008 and 2010, three of which have
123. Crawford et al., supra note 26, at 170. One study of patients treated showed
10.8% perceived problems after switching that were attributed to generic substitution. In
another survey of eighty-one patients, fourteen percent reported problems when
switching to a generic product. Id.
124. Wilner, supra note 31, at 996.
125. R. T. Burkhardt et al., Lower Phenytoin Serum Levels in Persons Switched From
Brand to Generic Phenytoin, 63 NEUROLOGY 1494, 1494 (2004), available at
http://www.neurology.org/ cgi/content/abstract!63/8/1494. The PHT concentration on the
brand name drug before generic substitution was 17.7 +/- 5.3 mg/L, which decreased to
12.5 +/- 2.7 mg/L after substitution of generic, and then increased to 17.8 +/- 3.9 mg/L
after the brand name was re-introduced. Id. The study concluded that "brand and generic
PHT do not yield equivalent concentrations in some patients and substitution should not
be permitted without physician notification." Id.
126. Rubenstein, supra note 34, at Al. "State legislation can move 'from idea, to
passage, to governor's signature in 90 days, sometimes faster than that ... [s]o the action
is in the states."' Id. (quoting Jan Faiks, director of state policy for the Pharmaceutical
Research and Manufacturers of America (PhRMA)).
127. Division of Government Affairs, Epilepsy Foundation, AED Patent Exclusivity
Expiration and the Number of Generic Manufacturers (2007) (unpublished, on file with
author); see ORANGE BOOK, supra note 27, add. Patent and Exclusivity Information at 37,
38, 77, 109, 148.
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generic forms already approved by the FDA.128 In light of these new generic
drugs and the FDA's announcement to accelerate the approval of generic
drugs, 129 the Foundation feels it necessary to act expeditiously.
B. State Legislation Restricting Substitution of Generic Drugs
The Foundation is not opPosed to generic drugs nor does it promote the
use of brand name drugs. T Rather, the Foundation seeks to ensure that
epileptic patients continue to receive the medication that works for them and
to avoid substituting medications without the informed consent of both the
physician and the patient.' 31 The legislative purpose is to allow for "truly
informed decision making" and to assure monitoring of potential
problems. 132 In 2007 and 2008, twenty-four states considered some form of
restriction, but only four have passed legislation: Hawaii, Tennessee,
Illinois, and Utah.133 The legislation passed by each of these states deserves
both praise and critique.
128. Id. (Patent exclusivity expires: Depakote - 2008, Topamax - 2008, Lamictal -
2009, Trileptal - 2009); Press Release, U.S. Food and Drug Admin., FDA Approves First
Generic Versions of Trileptal (Oct. 9, 2007), available at http://www.fda.gov/bbs/
topics/NEWS/2007/NEWO 1721 .html.
129. AP, FDA to Accelerate Approval of Generic Drugs: Agency Aims to Increase
Number, Availability of Affordable Meds, Oct. 4, 2007, http://www.msnbc.msn.com/id/
21137275.
130. Bill Murphy, Director, State Gov't Relations, Epilepsy Found., Address at the
Epilepsy Foundation's Annual Leadership Conference: Epilepsy Prescription Protection
Legislation (Sept. 28, 2007).
131. Id.
132. Id.
133. Rockoff, supra note 2, at Al; Forum of America's Ideas, supra note 11; see
Rubenstein, supra note 34, at Al (stating that as of July 2007, twenty-five states had
considered some form of restriction, including Hawaii, which passed legislation in 2003).
Wyoming considered but failed to pass an amendment to section 33-24-148 adding
section (h), which was proposed to read "A pharmacist may not substitute an anti-
epileptic [sic] drug or formulation of an anti-epileptic [sic] drug, prescribed for the
treatment of seizures, without the written consent of the prescribing physician." H.R.
317, 59th Leg., 636th Sess. (Wyo. 2007); see also WYo. STAT. ANN. § 33-24-148 (2007);
HAW. REV. STAT. ANN. § 328-92(c) (LexisNexis 2008); 225 ILL. COMP. STAT. ANN
85/26(c) (West 2007).
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In 2003, Hawaii became the first state to pass any form of restrictive
legislation on the substitution of generic antiepileptic drugs. Section 328-
92(c) states, "[t]he pharmacist shall not substitute an equivalent generic
drug product for any prescription for an anti-epileptic [sic] drug, except
upon the consent of the practitioner and the patient or the patient's parent or
guardian." 134 While the Hawaii state legislature should be praised for being
the first to enact limitations that require the pharmacist to gain the consent of
both the physician and the patient, the legislation is too restrictive. Hawaii's
drug product selection law is limited to the substitution of an "equivalent
generic drug product."' 35 Hawaii's statute restricts substitution of a brand
name drug for a generic drug and a generic drug for a different generic
version of that drug; however, the statute fails to cover the possibility that a
generic drug may be substituted for a brand name drug, or a brand name
drug for another brand name drug. Although these omitted substitutions are
less likely to occur, it is not logical to ignore a potential substitution that can
have the same catastrophic effect.
In June 2007, Tennessee passed a drug product selection law that requires
a pharmacist to provide notification to the patient and the physician before
substituting an antiepileptic drug, but the law does not require consent.
Section 53-10-210(b) states, "[a] pharmacist . . . shall provide notification to
the patient . . . before interchanging one . . . anti-epileptic [sic] drug for
another . .. anti-epileptic drug [sic] . . . [and] [t]he prescriber . . . shall also
be notified prior to the interchange. ' 36 By limiting the restriction to a
notification, the Tennessee statute has taken away the prescribing
physician's authority and given it to the pharmacist. Whether the patient is
initiating antiepileptic therapy, is well-controlled on antiepileptic drug
therapy, or is a high-risk patient, the decision regarding which medication to
prescribe is best left to the person who knows and is monitoring the patient:
the physician.' 37 For example, if the patient is initiating treatment or is a
high-risk patient, the physician, not the pharmacist, will know which
treatments have or have not worked and which medications are the most
appropriate. If the patient is a well-controlled patient, then the switch should
be avoided if possible. In addition, the Tennessee statute further limits a
pharmacist's requirement to notify to "instances where the patient's epilepsy
134. HAW. REV. STAT. ANN. § 328-92(c) (LexisNexis 2008) (emphasis added).
135. Id. § 328-92(a)(1).
136. TENN. CODEANN. § 53-10-210(b) (Supp. 2007).
137. See Kramer et al., supra note 5, at 50-51.
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or seizures are currently being controlled. ,,3 In effect, the state limits
notification by a pharmacist to cases where substitution should be most
avoided. If the pharmacist knows the patient is initiating treatment or is not
well-controlled, the Tennessee statute allows the pharmacist to make a
substitution to a drug the pharmacist finds appropriate, without notifying the
physician. The law is so limited that it marginally benefits a small
population of people with epilepsy.
One benefit of the Tennessee statute is its definition of "interchange."
Interchange is defined to include "substitution of a generic version for a
brand version, a brand version for a generic version, or a generic version for
a generic version by a different manufacturer."' 139 While this definition is an
improvement from the definition in the Hawaii statute, it is not complete.
By including "a generic version for a generic version by a different
manufacturer" in its definition of interchange, the Tennessee statute leaves
open the narrow possibility of a manufacturer making more than one
bioequivalent generic drug. The definition of interchange also fails to
consider the substitution of a brand drug for another brand drug. Like the
Hawaii statute above, Tennessee fails to define all possible types of
substitutions.
Illinois' drug product selection law, passed in October 2007, does require
a pharmacist to obtain notification and consent before interchange of an
antiepileptic drug, but only when a "prescribing physician has indicated on
the original prescription 'dispense as written' or 'may not substitute'....",140
In addition, the statute fails to adequately define interchange. As currently
interpreted and enforced, "dispense as written" instructions only prevent
switching from a brand name drug to a generic drug. A physician who
specifies "dispense as written" will not prevent the pharmacist from
substituting a generic drug made by one manufacturer for another generic
drug made by a different manufacturer. 41 Without an adequate definition of
138. TENN. CODEANN. § 53-10-210(b) (Supp. 2007).
139. Id. § 53-10-210(a)(3).
140. 225 ILL. COMP. STAT. ANN. 85/26(c) (West 2007).
When the prescribing physician has indicated on the original prescription
"dispense as written" or "may not substitute," a pharmacist may not
interchange an anti-epileptic drug or formulation of an anti-epileptic drug
for the treatment of epilepsy without notification and the documented
consent of the prescribing physician and the patient or the patient's parent,
legal guardian, or spouse.
Id.
141. Murphy, supra note 130.
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interchange, Illinois' statute only requires notification and consent when
switching from a brand name drug to a generic drug.
Most recently, Utah amended its drug product equivalents law in March
2008. Like the Tennessee statute, Utah's drug product selection law only
requires a pharmacist to provide notification to the physician before
substituting an antiepileptic drug, but it does not require consent.142 Like the
Illinois drug product selection law, Utah only requires notification when the
"practitioner . . . indicate[s] . . . by writing 'dispense as written' or . . .
signing ... where two lines have been printed. .. 'dispense as written' ...
." Unlike Hawaii, Tennessee, and Illinois, Utah has a complete definition
of "substitutes" (the word "interchange" is used in the Tennessee statute).
"Substitutes" is defined to mean "a generic drug for another generic drug; a
generic drug for a nongeneric [sic] drug; a nongeneric [sic] drug for another
nongeneric [sic] drug; or a nongeneric [sic] drug for a generic drug."
144
Utah's drug product equivalents law clearly covers all possible types of
substitutions.
A major flaw in Utah's statute, however, can be found in the last clause.
Section 58-17b-605(7)(d) states that "[n]otification ... is not reuired if the
drug product equivalent is paid in whole or in part by Medicaid." It seems
illogical not to extend the protections of this statute to the low-income
residents of Utah who are living with epilepsy. The clause singles out the
group that is the least capable of financially coping if a breakthrough seizure
were to occur and creates an unneeded barrier between the low-income
patient and his or her prescribing physician. There is no case law
interpreting the Hawaii, Tennessee, Illinois, or Utah antiepileptic statutes,
and to date, no challenges have been filed.
IV. SUGGESTED STATUTE
A. Proposed Legislation
The proposed legislation does not prohibit substitution, but is only
intended to prevent substitution without the informed consent of both
physician and patient.
142. UTAH CODE ANN. § 58-17b-605 (7)(c) (2008).
143. Id. § 58-17b-605 (5)(a), 7(b).
144. Id. § 58-17b-605 (7)(a).
145. Id. § 58-17b-605 (7)(d).
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(a) Definitions for use in this section:
(1) Antiepileptic drug means (i) any drug prescribed for the treatment of
epilepsy or (ii) a drug used to treat or prevent seizures.1
46
(2) Epilepsy means a neurological condition characterized by recurrent
seizures.
1 47
(3) Seizure means a brief disturbance in the electrical activity of the
brain.
148
(4) Substitute means the dispensing of one antiepileptic drug for a
different antiepileptic drug, which includes the substitution of:
(i) a generic drug for a brand drug;
(ii) a brand drug for a generic drug;
(iii) a generic drug for another generic drug; or
(iv) a brand drug for another brand drug.
149
(b) A pharmacist, pharmacy intern or a pharmacy technician shall not
substitute an antiepileptic drug or a formulation of an antiepileptic
drug for the treatment of epilepsy or seizures, except upon the
notification and consent of the prescribing physician and the patient or
the patient's parent, legal guardian, or spouse. 50
B. The Legislation 's Effect on Pharmacists and Health Care Costs
The additional burden placed on pharmacists is minimal and not
unreasonable. Any hardship created by requiring pharmacists to ask doctors
and patients for permission before substituting an antiepileptic drug is
outweighed by the need to assure personal and public safety. The one or two
percent of the population who rely on antiepileptic medication represent a
146. This language is derived primarily from the language in 225 ILL. COMP. STAT.
ANN. 85/26(b) (West 2007); TENN. CODEANN. § 53-10-210(a)(1) (Supp. 2007).
147. This language is derived primarily from the language in 225 ILL. COMP. STAT.
ANN. 85/26(b) (West 2007); TENN. CODEANN. § 53-10-210(a)(2) (Supp. 2007).
148. This language is derived primarily from the language in 225 ILL. COMP. STAT.
ANN. 85/26(b) (West 2007); see also TENN. CODE ANN. § 53-10-21 0(a)(4) (Supp. 2007).
149. This language is derived primarily from the language in TENN. CODE ANN. § 53-
10-210(a)(3) (Supp. 2007) and the language in UTAH CODE ANN. § 58-17b-605 (7)(a)
(2008).
150. See 225 ILL. COMP. STAT. ANN. 82/26(c) (West 2007); see also TENN. CODE ANN.
§ 53-10-210(b) (Supp. 2007). See generally HAW. REV. STAT. ANN. § 328-92 (2003).
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small portion of the billions of dollars spent on pharmaceutical products and
the volume of prescriptions dispensed by pharmacists everyday.'
51
Pharmacists contact physicians on a regular basis about prescriptions and
often talk to patients and offer their advice. There is no evidence that the
proposed legislation creates an undue burden on a pharmacist to obtain
permission of both the physician and the patient before substituting an
antiepileptic drug.
152
The proposed legislation does not require dispensing only brand name
drugs or the most expensive drugs. The legislation requires the physician
and the patient to be informed when a switch is suggested by the pharmacist,
or encouraged or required by an insurer's drug formulary. This places the
decision-making in the hands of the physician and patient to determine what
is medically necessary. There is no evidence of any financial consequence
to this proposed legislation. At a minimum, the legislation would save
money on unnecessary doctor and emergency room visits, and further reduce
the consequences of uniformed substitutions.1
53
V. RECOMMENDATIONS
Experts have called on the FDA to "fund or conduct research to identify
the optimum [methods] for determining bioequivalence for generic
[antiepileptic drugs]. 54  In view of inconsistent effects of so-called
bioequivalent drugs, the parameters for bioequivalence established in 1984
need to be, at the very least, reevaluated. The FDA needs to improve its
monitoring of approved generic antiepileptic drugs to assure accurate
reporting of adverse reactions to antiepileptic drugs. Currently, the only
reporting is voluntary. The FDA encourages epileptic patients and
151. Murphy, supra note 130.
152. Id. In addition, present communication systems allow a pharmacist to
communicate with the physician in a variety of ways and to obtain a particular
medication that is not in stock in a relatively short period of time. Id. As a practical
effect, a burden might be placed on the patient who seeks to fill his or her prescription at
night or on the weekends when his or her physician is unavailable.
153. Id.
154. Schachter, supra note 49; see also Epilepsy Foundation, An Interview with Steve
C. Schachter, http://www.epilepsyfoundation.org/generics/schachterinterview.html (last
visited Oct. 11, 2008) [hereinafter Schachter Interview].
155. Schachter, supra note 49; see Schachter Interview, supra note 154.
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physicians to report breakthrough seizures on the FDA website or by calling
an FDA hotline.
156
Providing awareness education is an important and practical step to take.
Developing programs to educate physicians and health care providers on the
issues associated with antiepileptic drug substitution could reduce the risk of
breakthrough seizures. Awareness education should provide guidelines
outlining safety goals and risks associated with antiepileptic substitution.'
57
The guidelines should educate physicians and health care providers on the
different types of patients and the goals for each, stressing that patients
whose seizures are controlled should not have their antiepileptic medication
switched unless medically appropriate. 58 Physicians should be aware that
maintaining patients on the same drug might require patients to pay more for
their medications. 159 This will allow physicians to discuss alternatives with
their patients.' 60 If a switch is determined to be appropriate, the guidelines
should educate physicians on how to properly monitor patients to achieve
optimal results.
Education programs targeting public and private payers of health
insurance will facilitate the development of drug formularies and policies to
156. Epilepsy Foundation, Reporting Problems with Medication Switches,
http://www.epilepsyfoundation.org/generics/problems.html (last visited Oct. 11, 2008).
157. Schachter, supra note 49; Haskins et al., supra note 85, at 104; see Schachter
Interview, supra note 154; Crawford et al., supra note 26, at 174 ("[J]t is prudent for
patients, neurologists and pharmacists to be aware of the issues and to approve generic
prescribing of AEDs for certain high-risk patients prior to it being instituted.").
158. Kramer et al.' supra note 5, at 50-51 ("Most practice guidelines recommend that
[well-controlled] patients should not be switched to another form of the drug."); see
Crawford et al., supra note 26, at 169 (stating "a patient stabilised [sic] on one AED may
be at risk of that control being lost if the prescription is changed to a formulation from a
different manufacturer.").
159. See Kramer et al., supra note 5, at 46; Heaney & Sander, supra note 41, at 466;
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161. Schachter, supra note 49; Haskins et al., supra note 85, at 104 ("[T]he generic
substitution practice is not well understood by most patients with epilepsy and not
completely understood by physicians."); Heaney & Sander, supra note 41, at 465;
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ensure patient access to antiepileptic drugs.' The goal is to have adequate
protections in place to prevent mandatory substitution of antiepileptic
medications. If substitution is unavoidable, for example, in the case of drug
formularies, safeguards should be enacted to prevent patients from being
penalized financially or overly burdened by administrative procedures if
they experience treatment failure following an antiepileptic substitution.'
63
Awareness education should place an emphasis on informing people with
epilepsy of the potential risks of switching their antiepileptic medication
without medical guidance.1 64 Many patients are unaware of these risks and
may make uninformed decisions based solely on the lower costs of available
generic drugs. Patients should be encouraged to discuss all antiepileptic
medication switches with their physician. 65 Patients need to be aware of the
many practical things they can do to prevent switches in their medication,
such as knowing what their medication looks like and who manufactures it,
so that they can monitor their medications for any unknown substitutions.
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Most importantly, "pharmacists should be educated on the unique nature
of epilepsy" and the risks of antiepileptic substitution to the patient and
society. In addition, pharmacists need to be aware of the need to consult
162. Schachter, supra note 49; see Schachter Interview, supra note 154; Abbott Lab.
2005 WL 1323435, at *15; see Drug Formularies, supra note 13; Parks, supra note 70 at
2186; see CIGNA, supra note 78.
163. Drug failure may require further doctor visits, emergency room visits, or a switch
back to their previous medication. See Crawford et al., supra note 26, at 169.
164. Schachter, supra note 49; Crawford et al., supra note 26, at 167 (listing loss of
driver's license and loss of employment as social implications and risk of injury and loss
of self-esteem as personal implications); see Schachter Interview, supra note 154;
Epilepsy Foundation, Terms, http://www.epilepsyfoundation.org/generics/glossary.html
(last visited Oct. 11, 2008); see also Spencer, supra note 58, at 14 (suggesting people
diagnosed with epilepsy are three times more likely to commit suicide than the general
population).
165. Schachter, supra note 49.
166. Schachter, supra note 49; see Schachter Interview, supra note 154.
167. Crawford et al., supra note 26, at 167-69; Schachter, supra note 49; Kramer et
al., supra note 5, at 48; see also Spencer, supra note 58, at 14.
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with physicians and the importance of exercising caution when switching
among different manufacturers of the same product.'
68
CONCLUSION
The bottom line is that pharmacists need to obtain notification and consent
from both the patient and the patient's physician before substituting
antiepileptic drugs. Generic drugs are a welcomed part of our country's
health system and a necessity for keeping the cost of prescription
medications down. Generic antiepileptic drugs can save numerous epileptic
patients money in the end, but the administration of these drugs needs to be
monitored closely. The only problematic step in the process from the
physician prescribing the medication to the patient taking the antiepileptic
drug is the pharmacist filling the prescription. With proper education
programs and legislative safeguards in place, generic antiepileptic drugs will
be more effective in producing savings to health care providers and patients.
The bioequivalence standard established by the FDA must be reevaluated
for its effectiveness and applicability to generic drugs in all treatment areas.
As demonstrated by antiepileptic drugs, the one-size-fits-all standard of
bioequivalence is inappropriate for creating safe and effective generic drugs
in all applications. The FDA's bioequivalence standard is a generic standard
for generic drugs. Due to the unique nature of epilepsy and the potential
danger of inaccurate medications, the archaic standard for bioequivalence
has been exposed. Other medications with narrow therapeutic ranges have
been shown to have similar problems. Studies on generic antidepressant
drugs and generic blood thinners used to treat heart conditions also have
called into question the reliability of the FDA's testing and standards for
approving these types of drugs.' 69 These studies reveal that the generic
drugs reported as causing patients problems were within FDA limits of
acceptability.170 These studies require additional investigation by the FDA.
168. Schachter, supra note 49; Kramer et al., supra note 5, at 50-51; see Schachter
Interview, supra note 154.
169. Jacqueline Stenson, Report Questions Generic Antidepressant:
ConsumerLab.com Finds Cheaper Drug May Not Work the Same as Brand, MSNBC,
Oct. 12, 2007, http://www.msnbc.msn.com/id/21142869.
170. See id ConsumerLab.com compared the brand name antidepressant, Wellbutrin,
to its FDA approved generic counter part, Budeprion, using a test-tube test and found that
Budeprion dissolves faster releasing thirty-four percent of the active ingredient within the
first two hours, compared to Wellbutrin that releases only eight percent in the same time
period. Melinda Beck, Inexact Copies: How Generics Differ From Brand Names, WALL
ST. J., Apr. 22, 2008, at DI. Patients switched to Budeprion reported effects ranging
from tremors, headaches, anxiety and sleep disturbances, to depression and thoughts of
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Legislative safeguards can be put into place to protect consumers who use
generic medications, but the problem is more deeply rooted in the FDA's
standard for bioequivalence.
suicide caused by receiving four times the active ingredient in the first two hours and not
enough of the active ingredient throughout the rest of the day. Id.
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